Therefore, we propose the novel survival index (SI), an outcome marker combining the prognostic values of hematologic inflammation and cachexia markers (NLR, BMI, and albumin) with clinical characteristics (T classification, N classification, and tumor invasion of the OL) and aimed to test its prognostic significance in patients with SNSCC. This evidence concerns the gene ALB and Cachexia.